UNSPSC 51413108: Udenafil

This classification denotes a cgmp phosphodiesterase inhibitor, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier L5IB4XLY36. European Medicines Agency schedules Udenafil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32099. Udenafil generally arises in the molecular formula C25H36N6O4S.

The term UDENAFIL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 20, no. 1, 2006, list 55.) UDENAFIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

UNSPSC 51413108 Udenafil is a Commodity code covering pharmaceutical products supplied to state and local health agencies, fire rescue departments, and health benefit programs. Recent state and local activity under this code shows solicitation for advanced life support medications, generic pharmaceuticals, and over-the-counter products used in emergency medical services and pharmacy benefit administration. The scope of work includes sourcing, warehousing, and delivery of medications with specific expiration, shelf-life, and safety compliance requirements, including FDA certification, Good Manufacturing Practices (cGMP) compliance, and Drug Supply Chain Security Act adherence. State and local issuing bodies span city purchasing departments (Tampa Fire Rescue), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving multiple states including Oregon). Vendors typically must maintain relationships with authorized wholesalers, manage product recalls and expired inventory, and warrant materials against defects for minimum periods.

Recent activity centers in Texas, Florida, and Minnesota, with MMCAP's cooperative structure extending reach across participating states. The City of Tampa issued IFB 26P00188 on April 24, 2026, for advanced life support medications (labetalol, epinephrine, adenosine, diltiazem) with response due April 8, 2026 and an estimated contract value of $40,000, requiring delivery within ten days and nine-month minimum expiration; the contract includes a 5 percent bid discount for Small Local Business Enterprises. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, with no formal budget or timeline established at the information-gathering stage. The Minnesota Department of Administration, through MMCAP, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products across state and local facilities in multiple states, with response due March 26, 2026 and evaluation weighted heavily on price competitiveness (75 percent), requiring vendors to work through authorized wholesalers and pay a 3 percent administrative fee.